BIOLINERX
Careers | Contact Us
search

Press Releases
July 6, 2009
Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI).
June 21, 2009
BioLineRx’s CEO Dr. Morris Laster: “BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions.”
June 21, 2009
BioLineRx’s CEO Dr. Morris Laster: “These results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition”
June 1, 2009
Fifteen Patients Successfully Treated With BL-1040 With No Complications;
Five Patients Completed Six Months Follow up Period with prevention of LV remodeling
May 18, 2009

BioLineRx announced that data from preclinical behavioral models of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented today at the Society of Biological Psychiatry (SOBP) 64rd Annual Scientific Convention & Meeting held in Vancouver, Canada May 14-16, 2009.

April 30, 2009
BioLineRx completed the enrolment of 360 schizophrenia patients for BL-1020 phase IIb trial. The company completed the recruitment phase two months ahead of schedule. BioLineRx started the phase IIb trial, aimed at evaluating the efficacy, tolerability and safety of BL-1020 in July 2008.
January 12, 2009
Five out of 30 patients already safely treated. Final results of trial expected in Q3 2009
November 12, 2008
Yissum Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to develop and commercialize BL-5040, a new anti-hormone for the treatment of inflammatory diseases.
July 16, 2008
BL-1040, a novel myocardial implant for the treatment of acute myocardial infarction (MI), has been selected as one of the Top 10 most promising cardiovascular projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
301-309  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31